PHASIQ’s proprietary Micropatterned Phase-Separation Technology™ enables scientists to measure protein levels in a multiplex, cost-effective and cross-reaction free manner, thereby accelerating protein diagnostics and therapeutics development. PHASIQ has exclusive worldwide licenses to three US and PCT patents and pending patents for our core technology from the University of Michigan. PHASIQ is developing research-use-only multiplex ELISA protein immunoassay kits for targeted conditions within immune disorders, cardiovascular diseases, and cancer.
Location: United States, Michigan, Southeast
Employees: 1-10
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Innovation... | innovation... |
Mentions in press and media 3
| Date | Title | Description |
| 21.09.2015 | Phasiq Raises Funding | Phasiq, an Ann Arbor, Michigan-based healthcare company that provides a solution to test for multiple proteins on a single patient sample, raised funding. The amount of the deal was not disclosed. The Zell Lurie Commercialization Fund, in c... |
| 17.09.2015 | Proteomics assay startup gets funding from UM’s student-run fund | The underlying research comes from University of Michigan professor Shuichi Takayama, who works in the field of macromolecular science and biomedical engineering. Promoted Telemedicine’s potential to provide healthcare to the world’s most v... |
| - | Proteomics assay startup gets funding from UM’s student-run fund | Phasiq, an Ann Arbor proteomics startup, just received a pre-seed round of funding from the student-run Zell Lurie commercialization fund at the University of Michigan, it said a statement. Phasiq is developing a multiplex assay that’s mean... |